{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":".05","upperLimit":".85","value":".4"},{"groupId":"OG001","lowerLimit":".006","upperLimit":".81","value":".25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"description":"The proportion of successes will be estimated in each arm independently by the number of successes divided by the total number of evaluable patients. Confidence intervals for the true success proportion will be calculated according to the approach of Duffy and Santner. A confirmed tumor response is defined to be a partial response or better noted as the objective status on two consecutive evaluations while receiving lenalidomide and dexmethasone (Arm A) or pomalidomide and dexamethasone (Arm B). All patients meeting the eligibility criteria who have signed a consent form and have begun treatment will be evaluable for response.The International Myeloma Working Group (IMWG) uniform response criteria (Rajkumar et al, 2011) will be used to assess response to therapy.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive lenalidomide PO daily on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing progressive disease may crossover to arm B.\n\n\\>\n\n\\> Dexamethasone: Given PO\n\n\\>\n\n\\> Lenalidomide: Given PO","id":"OG000","title":"Arm A (Lenalidomide, Dexamethasone)"},{"description":"Patients receive pomalidomide PO daily on days 1-21 and dexamethasone as in arm A. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\n\\>\n\n\\> Dexamethasone: Given PO\n\n\\>\n\n\\> Pomalidomide: Given PO","id":"OG001","title":"Arm B (Pomalidomide, Dexamethasone)"}],"paramType":"NUMBER","populationDescription":"All patients that received treatment were evaluable for response","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Proportion of Confirmed Tumor Responses Defined to be a Partial Response or Better Noted as the Objective Status on Two Consecutive Evaluations","type":"PRIMARY","unitOfMeasure":"proportion of participants"}